VEGFR2, also known as kinase insert domain receptor (KDR) or fetal liver kinase-1 (FLK-1), is a transmembrane receptor tyrosine kinase encoded by the KDR gene located on chromosome 4q12. As the primary high-affinity receptor for vascular endothelial growth factor (VEGF), particularly VEGF-A, VEGFR2 is a critical regulator of vascular development, endothelial cell function, and vascular permeability. The protein consists of an extracellular region containing seven immunoglobulin-like domains, a transmembrane domain, and an intracellular region harboring the catalytic tyrosine kinase domain. VEGFR2 is predominantly expressed on endothelial cells but also appears on hematopoietic progenitor cells, megakaryocytes, and certain neuronal populations.
Function and Biology
...
VEGFR2 (KDR) Protein
Overview
VEGFR2, also known as kinase insert domain receptor (KDR) or fetal liver kinase-1 (FLK-1), is a transmembrane receptor tyrosine kinase encoded by the KDR gene located on chromosome 4q12. As the primary high-affinity receptor for vascular endothelial growth factor (VEGF), particularly VEGF-A, VEGFR2 is a critical regulator of vascular development, endothelial cell function, and vascular permeability. The protein consists of an extracellular region containing seven immunoglobulin-like domains, a transmembrane domain, and an intracellular region harboring the catalytic tyrosine kinase domain. VEGFR2 is predominantly expressed on endothelial cells but also appears on hematopoietic progenitor cells, megakaryocytes, and certain neuronal populations.
Function and Biology
VEGFR2 mediates the biological effects of VEGF-A through ligand-induced receptor dimerization and autophosphorylation of multiple tyrosine residues within the kinase domain. Upon VEGF-A binding, VEGFR2 undergoes conformational changes that enable recruitment and phosphorylation of downstream signaling molecules, including phospholipase C-gamma (PLCγ), extracellular signal-regulated kinases (ERK1/2), and the phosphoinositide 3-kinase (PI3K)/AKT pathway. These cascades regulate critical endothelial cell functions including proliferation, survival, migration, and differentiation. Beyond vascular development, VEGFR2 signaling controls vascular permeability through VE-cadherin modulation and endothelial barrier function. The receptor also participates in angiogenic sprouting and vascular maintenance through integration with Tie2 signaling and angiopoietin pathways.
Role in Neurodegeneration
VEGFR2 dysfunction represents an emerging factor in multiple neurodegenerative disease pathologies. In Alzheimer's disease, impaired cerebral angiogenesis and blood-brain barrier (BBB) compromise are associated with reduced VEGF-VEGFR2 signaling, contributing to amyloid-beta accumulation and neuroinflammation. Decreased VEGFR2 expression correlates with cerebrovascular rarefaction observed in Alzheimer's patients, leading to reduced cerebral blood flow and neuronal hypoxia. In Parkinson's disease, VEGFR2 dysfunction contributes to dopaminergic neuron vulnerability through compromised vascular support and impaired neuroprotective signaling. During ALS pathogenesis, motor neuron degeneration is accompanied by progressive neurovascular dysfunction, partly attributed to VEGFR2 signaling defects that weaken the neurovascular unit. Huntington's disease also exhibits vascular abnormalities linked to altered VEGF-VEGFR2 signaling, exacerbating neuronal stress. The blood-brain barrier deterioration common to all these conditions involves VEGFR2-dependent endothelial dysfunction, permitting toxic protein infiltration and neuroinflammatory cell recruitment.
Molecular Mechanisms
In neurodegenerative contexts, VEGFR2 signaling dysregulation occurs through multiple mechanisms. Reduced VEGF-A production by stressed neurons and glia diminishes VEGFR2 ligand availability. Pathological protein aggregates may directly impair VEGFR2 expression or function in endothelial cells. Neuroinflammatory mediators like TNF-α and IL-1β downregulate VEGFR2 expression, creating a self-amplifying cycle of vascular dysfunction. Oxidative stress inactivates VEGFR2 signaling through tyrosine phosphatase activation and reactive oxygen species-mediated receptor damage. Additionally, age-related VEGFR2 downregulation in the cerebrovasculature reduces angiogenic capacity and endothelial regeneration, exacerbating age-dependent neurodegeneration.
Clinical and Research Significance
Pharmacological VEGFR2 activation represents a therapeutic strategy under investigation for multiple neurodegenerative diseases. VEGFR2 agonists and VEGF gene therapy approaches aim to restore cerebrovascular function and promote neuroprotection. Small-molecule VEGFR2 inhibitors, while useful in cancer treatment, may have detrimental neurovascular consequences requiring careful consideration. Biomarkers reflecting VEGFR2 pathway dysfunction in cerebrospinal fluid and blood are being explored for disease diagnosis and therapeutic monitoring. Understanding VEGFR2 signaling restoration offers potential for combination therapies targeting both neuroinflammation and cerebrovasculature integrity.